Frailty and multi-morbidities should not govern oral anticoagulation therapy prescribing for patients with atrial fibrillation - 20/02/19
Doi : 10.1016/j.ahj.2018.10.003
Ameenathul M Fawzy, MB a, Brian Olshansky, MD b, Gregory Y H Lip, MD a, ⁎ 
a Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
b University of Iowa Hospitals, Iowa City, Iowa
⁎Reprint requests to Prof. GYH Lip, MD.: Institute of Ageing and Chronic Disease – Liverpool Centre for Cardiovascular Science, University of Liverpool, William Henry, Duncan Building, 6 West Derby Street Liverpool, L7 8TX United Kindgom.Institute of Ageing and Chronic Disease – Liverpool Centre for Cardiovascular ScienceUniversity of LiverpoolWilliam Henry, Duncan Building, 6 West Derby Street Liverpool, L7 8TXUnited Kindgom
Le texte complet de cet article est disponible en PDF.
| Declaration of interests: GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. Olshansky: Boehringer Ingelheim, Amarin, Lundbeck. |
|
| This editorial refers to ‘Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial’ by Alexander et al. |
© 2018
Elsevier Inc. Tous droits réservés.
Vol 208
P. 120-122 - février 2019 Retour au numéro
Article précédent
- Information for Readers
- The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design
- Kristina Lambrakis, John K. French, Ian A. Scott, Tom Briffa, David Brieger, Michael E. Farkouh, Harvey White, Anthony (Ming-Yu) Chuang, Kathryn Tiver, Stephen Quinn, Billingsley Kaambwa, Matthew Horsfall, Erin Morton, Derek P Chew
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?